Full-Time

Principal Software Engineer

AI-Native

RxSense

RxSense

201-500 employees

PBM software platform with real-time analytics

Compensation Overview

$210k - $275k/yr

Remote in USA

Remote

Remote within the United States; must have work authorization in the United States.

Bachelor's

Category
Software Engineering (2)
,
Required Skills
Python
Machine Learning
TypeScript
.NET
DevOps

Get referred to RxSense

See people who can refer or advise you

Requirements
  • 8+ years of professional software engineering experience, with demonstrated Staff, Principal, or Architect-level scope — e.g., owning system architecture end-to-end, driving technical strategy across multiple teams, or being accountable for critical production systems.
  • Depth across backend and AI/ML systems, working in some combination of C#/.NET, Python, and TypeScript.
  • Experience with LLM observability, prompt and response evaluation, or agentic system testing
  • A track record of setting technical standards that other engineers and teams adopt.
  • Strong communication skills, with the ability to align engineers and leadership around a shared technical direction.
  • Comfort working in an AI forward engineering environment, for example with agentic coding tools such as Claude Code.
  • Bachelor's degree in Computer Science, Engineering, or a related field preferred. Equivalent practical experience will be considered in lieu of a formal degree.
Responsibilities
  • Architect and build production systems across a multi language stack: C#/.NET services, Python AI and data pipelines, and occasional TypeScript
  • Set the example for an AI forward, high technical standard across the broader engineering organization, leading through craft rather than organization wide authority
  • Design and drive adoption of offline evaluation frameworks (test suites, golden datasets, regression harnesses wired into CI/CD) for LLM based and other non deterministic components
  • Build online evaluation and monitoring that continuously assesses live model and system behavior in production, including drift and regression detection
  • Partner with engineering leadership to surface systemic risks in AI features, such as reliability, correctness, and drift, and drive the fixes
  • Lead architecture reviews for major initiatives and mentor senior and staff engineers on system design, evaluation methodology, and AI forward practices
  • Prototype and ship new AI capabilities
Desired Qualifications
  • Experience in pharmacy benefits, healthcare, fintech, or another regulated, high stakes domain.
  • Familiarity with distributed systems tooling such as Kafka, gRPC, Grafana, and Dragonfly / Redis.
  • A good eye for clean, usable interfaces for the occasional front end work.

RxSense provides software solutions for the pharmacy benefits management (PBM) industry. Its core product is an enterprise platform that unifies PBM operations with real-time business intelligence and analytics, enabling clients to monitor performance, optimize models, and make data-driven decisions. The platform is modular and includes APIs that enable interoperability via standards like FHIR and NCPDP, supporting integration with other systems and speeding time to market through optional business accelerators. Real-time data, ad hoc reporting, and analytics help PBMs manage claims adjudication and improve care delivery. Compared with competitors, RxSense emphasizes a real-time, modular platform with ready-to-use accelerators and a strong emphasis on API interoperability to connect diverse healthcare systems. The company’s goal is to simplify complexity in PBM operations, improve efficiency, and empower clients with timely insights to run their benefits programs more effectively.

Company Size

201-500

Company Stage

Growth Equity (Venture Capital)

Total Funding

N/A

Headquarters

Boston, Massachusetts

Founded

2015

Get referred to RxSense

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • May 2026 RxUtility partnership expands RxSense pricing networks into another affordability workflow.
  • August 2026 TailorMed deal adds copay assistance for 2,200 brand-name drugs.
  • RxSense reported about 420 employees in March 2026 and remains actively hiring.

What critics are saying

  • Congress passed PBM reforms on February 3, 2026, tightening rebate and fee economics.
  • Walgreens Rx Savings Finder says RxSense alone determines discount-card pricing, concentrating pricing responsibility.
  • If SingleCare loses pharmacy contracts or employer adoption, RxSense's consumer savings engine erodes quickly.

What makes RxSense unique

  • RxIQ Enterprise powers SingleCare and Walgreens Rx Savings Finder with direct pharmacy contracts.
  • RxSense embeds adjudication, analytics, and APIs across PBMs, health plans, and retailers.
  • February 2026 Blue Genes partnership puts pharmacogenomics inside claims adjudication workflows.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Flexible Work Hours

Remote Work Options

Professional Development Budget

Mental Health Support

Growth & Insights and Company News

Headcount

6 month growth

12%

1 year growth

12%

2 year growth

11%
Yahoo Finance
Aug 4th, 2026
TailorMed and RxSense partner to surface copay assistance for 2,200+ brand-name medications

TailorMed and RxSense have partnered to integrate manufacturer copay assistance programmes into digital pharmacy marketplaces. The collaboration embeds TailorMed's affordability technology into RxSense-powered marketplace tools, allowing retail pharmacies to display manufacturer copay and foundation assistance programmes alongside cash-pay coupons. The integration covers over 2,200 brand-name medications, including Eliquis, Dupixent, Keytruda, Ozempic, and Zepbound. With one in three Americans unaware that drug manufacturer financial assistance programmes exist, the partnership addresses a gap for individuals searching for prescription savings. The combined offering enables pharmacy staff to connect customers with assistance programmes when they are actively searching for affordable medication options. TailorMed operates a medication success platform whilst RxSense provides pharmacy benefit solutions.

Healthcare Industry Today
May 20th, 2026
RxUtility and RxSense Partner to simplify access to prescription savings.

RxUtility and RxSense Partner to simplify access to prescription savings. NASHVILLE, TN, UNITED STATES, May 20, 2026 / EINPresswire.com / - RxUtility, the real-time medication affordability platform, and RxSense, a healthcare technology company delivering pharmacy benefit solutions that improve affordability and access, today announced a new partnership to help patients more easily find and access the lowest available price for their medications. Savings opportunities exist across insurance, cash pay, manufacturer programs, and discount cards, but they are fragmented, difficult to access, and rarely visible in one place. According to the Kaiser Family Foundation, 6 in 10 U.S. adults are concerned about affording their prescription medications, and demand for pricing transparency continues to grow. "People assume they're seeing the best price for their medication. Most of the time, they're not," said Miriam Paramore, Founder and CEO of RxUtility. "Savings are scattered across different programs, and they're not designed to show up when people actually need them. This partnership brings those options together in one place, so people can make a clear, informed choice. RxSense expands the depth of options in our platform, and together we share a mission to improve choice, transparency, and control for people." Through this partnership, RxSense will bring a scalable, API-driven platform that enables real-time access to prescription pricing and savings through a single integration, allowing RxUtility to incorporate pricing and pharmacy networks from RxSense's proprietary discount card brands, including SingleCare and Paramount Rx, into its workflows. Together, the companies deliver a more unified solution that improves price transparency and expands access to savings, making it easier for people to choose the lowest-cost option within a single workflow. For RxUtility, RxSense fills a key gap: a network layer that expands reach across payers, employers, and pharmacy partners. "Patients deserve to know they're getting the best price on their prescriptions, every time," said John Zevzavadjian, President of Enterprise and Partner Solutions at RxSense. "By combining RxUtility's workflow with RxSense's pricing infrastructure and savings networks, we're making that a reality. This partnership closes the gap between what patients pay and what they could pay, and that's exactly the kind of progress we're here to drive." About RxUtility RxUtility provides AI-native technology purpose-built to make medications affordable for consumers. RxUtility is the only company to connect providers, pharmacists, employers, payers and digital health partners with real-time access to all medication prices through its affordability platform. By embedding prescription affordability and transparency in these tech workflows, RxUtility reduces patient payment confusion, drives medication adherence and ensures equitable access to prescription drugs. Learn more at www.rxutility.com. About RxSense RxSense is a healthcare technology company delivering industry-leading pharmacy benefit solutions that help organizations improve affordability and access to prescription medications. Built on a modern, cloud-native platform, RxSense offers real-time claims adjudication, advanced analytics, and configurable tools that adapt to the needs of a dynamic healthcare landscape. RxSense is also the parent company of SingleCare and Paramount Rx, trusted brands that extend RxSense's mission of making medications more affordable and accessible to consumers nationwide. Headquartered in Boston, RxSense is committed to empowering its partners with smarter technology and consumer-centric models that drive better outcomes across the pharmacy benefit ecosystem. For more information, visit www.rxsense.com. Legal Disclaimer: EIN Presswire provides this news content "as is" without warranty of any kind. Healthcareindustrytoday do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.

Associated Press
Feb 23rd, 2026
Blue Genes partners with RxSense to embed pharmacogenomics into pharmacy benefit workflows

Blue Genes has partnered with RxSense to integrate pharmacogenomics insights into pharmacy benefit workflows at the point of claims adjudication. The collaboration will embed Blue Genes' precision medicine capabilities into RxSense's enterprise pharmacy technology platform, enabling real-time genetic insights to inform medication selection. The solution aims to help pharmacy benefit managers and plan sponsors reduce trial-and-error prescribing, minimise adverse drug reactions, and improve cost efficiency by identifying optimal medications and dosages before costly inefficiencies occur. By integrating pharmacogenomic data directly into adjudication workflows, the partnership seeks to transform genetic insights from siloed information into actionable decision-support tools. Blue Genes focuses on advancing pharmacogenomics to optimise medication outcomes, whilst RxSense provides pharmacy benefits solutions to healthcare organisations.

The Manila Times
Feb 23rd, 2026
Blue Genes Partners with RxSense to Deliver Actionable PGx at the Point of Adjudication

Blue Genes partners with RxSense to deliver actionable PGx at the point of adjudication. By GlobeNewswire February 23, 2026 The new partnership will enhance pharmacy benefit decision-making by embedding real-time genetic intelligence into adjudication workflows SCOTTSDALE, Ariz., Feb. 23, 2026 (GLOBE NEWSWIRE) - Blue Genes today announced a strategic partnership with RxSense, a leading healthcare technology company delivering innovative pharmacy benefits solutions, to integrate precision medicine insights directly into pharmacy benefit workflows, making pharmacogenomics (PGx) actionable at the point of adjudication. This collaboration will empower pharmacy benefit managers (PBMs) and plan sponsors to optimize medication decisions in real time, reducing trial-and-error prescribing and improving member outcomes. Through this partnership, Blue Genes' PGx capabilities will integrate directly into the RxSense enterprise pharmacy technology platform, enabling genetic insights to inform medication selection during the claims adjudication process. By embedding precision medicine into existing benefit infrastructure, the solution allows prescribers and payers to identify the right medication and dosage earlier-before costly inefficiencies and adverse reactions occur. "Our mission has always been to make precision medicine practical and scalable," said Nick Glimcher, CEO of Blue Genes. "We are excited to announce our partnership with RxSense, which will broaden Blue Genes' reach across more platforms, allowing members to receive pinpointed prescriptions and avoid trial-and-error prescribing. Together, we are helping PBMs and health plans move from reactive cost management to proactive clinical optimization." The combined solution will allow PBMs and plan sponsors to: * Reduce avoidable medication switches and therapy failures * Minimize adverse drug reactions linked to genetic variability * Improve member satisfaction through personalized prescribing * Enhance cost efficiency by aligning treatment with genetic compatibility Advertisement As prescription drug costs continue to rise, stakeholders are seeking smarter tools to balance financial stewardship with quality care. Embedding PGx insights directly into adjudication workflows ensures that genetic data is not siloed or underutilized, but instead becomes a real-time decision-support mechanism that aligns clinical efficacy with cost control. "This partnership reflects RxSense's commitment to advancing innovation in pharmacy benefits," said Ramzi Yacoub, Pharm.D., Chief Pharmacy Officer at RxSense. "By embedding precision medicine into our enterprise platform, we are strengthening the value of the benefit and enabling more informed medication decisions at the point of adjudication. Integrating pharmacogenomic insights into existing workflows will drive efficiency, reduce avoidable costs, and support a more personalized, outcomes-driven approach to pharmacy benefits." Together, Blue Genes and RxSense share a commitment to redefining healthcare with smarter, more efficient solutions that bridge innovation and operational simplicity. By making PGx actionable within established pharmacy benefit infrastructures, Blue Genes and RxSense are setting a new standard for personalized medication management at scale. About Blue Genes Blue Genes is a company focused on advancing pharmacogenomics (PGx) to optimize medication outcomes and eliminate trial-and-error prescribing. By translating genetic insights into actionable clinical guidance, Blue Genes enables PBMs, health plans, and healthcare organizations to improve medication effectiveness, reduce adverse events, and enhance cost efficiency. The company's technology integrates seamlessly into existing healthcare systems, transforming genetic data into practical decision-support tools that improve both patient experience and financial performance. About RxSense RxSense(R) is a healthcare technology company delivering industry-leading solutions for pharmacy benefits and prescription savings. RxSense's transformative enterprise solutions bring transparency, flexibility, and efficiency to pharmacy benefit administration, serving pharmacy benefit managers, employers, health plans, health systems, third-party administrators, new healthcare and pharmacy entrants, and healthcare technology companies. RxSense has been named among Fast Company's World's Most Innovative Companies, Forbes' America's Best Startup Employers, and Inc's Best in Business. For more information, visit rxsense.com. Media Contacts Nick Glimcher CEO, BlueGenes

Inside Telecom
Mar 2nd, 2025
Pharmaceutical AI Finally Disrupts Traditional Pharmacy Benefits Management

In January, AI in pharmacy saw its biggest shift in pharmacy benefits management (PBM) as RxSense launched its cloud-based RxIQ analytics platform, delivering real-time data insights and optimized efficiency for healthcare organizations.